We improve the lives of patients through the design of precise cancer therapeutics. Until now, RSK has been undruggable. Our work focuses on developing novel drugs targeting RSK, a driver in cancerous tumor growth and metastases.
RSK signalling controls the growth of at least 14 different types of cancer, including breast and prostate cancer. Our initial focus is on treating one of the most aggressive types of breast cancer, triple negative breast cancer (TNBC), which is where RSK was originally discovered in kinome-wide functional screens. In TNBC, there are limited options for treatment beyond chemotherapy for patients therefore, the demand for novel therapies like ours is extremely high.
We are leaders in the field of RSK inhibition and recently completed a first-in-human clinical trial with our lead candidate, PMD-026, in breast cancer patients.
Our patented cancer compounds position us in the lead to streamline our product to market through patient selection using a companion diagnostic to identify cancer patients who will optimally benefit from RSK targeted therapies.